立他司特滴眼液的功效

Efficacy

Ritalast eye drops 5% are indicated for the treatment of signs and symptoms of dry eye disease (DED). It binds to the integrin LFA-1 (lymphocyte function-associated antigen-1) and blocks the interaction between LFA-1 and its cognate ligand ICAM-1 (intercellular adhesion molecule-1). Litalast eye drops reduce T cell migration, T cell activation and pro-inflammatory cytokine release by blocking the LFA-1/ICAM-1 interaction, thereby blocking the dry eye inflammation cycle and reducing the inflammatory response. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

This study evaluated the efficacy of Ritalast eye drops in the treatment of dry eye disease (DED) in the real world. PATIENTS AND METHODS: Ophthalmologists and optometrists treating patients with DED were invited to participate through a healthcare provider (HCP)-based panel. HCPs completed a provider survey and provided data for chart review of up to five eligible patients with DED who were prescribed rifalast ophthalmic solution. Patient demographics, treatments, clinical characteristics, and outcomes (i.e., severity, signs, symptoms) were collected 6 months before index and 12 months after index.

Results: In this study, 517 HCPs provided 600 medical records. Of the 554 and 281 patients followed at 6 and 12 months after index, 512 (92.4%) and 238 (84.7%) patients, respectively, received rifaximide. Other DED-related treatments were used less frequently post-index than pre-index: over-the-counter artificial tear use (45.2% vs 75.5%), topical corticosteroid use (3.8% vs 18.8%), and any cyclosporine use (3.0% vs 20.5%).

Compared with those before the index, 3 months (n=571) and 12 months (n=320) after the index, fewer patients had dry eyes (47 [8.2%] and 16 [5.0%] vs 525 [87.5%]) and blurred vision (28 [4.9%] and 11 [3.4%] vs 346 [57.7%]), eye burning/stinging (25 [4.4%] and 8 [2.5%] vs 336 [56.0%]), depression (8 [1.4%], 9 [2.8%] vs 55 [9.2%]); fatigue (4 [7.7%], 1 [0.3%] vs 82 [13.7%]) and headache (1 [0.2%] and 0 vs 19 [3.2%]), mean Schirmer score (10.6 and 10 vs 6.3) and tear film break-up time (7.3 and 8.0 vs 4.8) were higher.

CONCLUSIONS: Most patients underwent continued treatment with Ritalast eye drops 6 months after index, and the overall treatment burden was reduced. Signs and symptoms of DED, including impact on quality of life, improved significantly at 3 and 12 months after initiation of Ritalast eye drops.

Recommended related articles:

References

Hovanesian JA, Nichols KK, Jackson M, Katz J, Chan A, Glassberg MB, Sloesen B, Korves C, Nguyen C, Syntosi A. Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease. Clin Ophthalmol. 2021 Mar 8;15:1041-1054. doi: 10.2147/OPTH.S296510. PMID: 33727786; PMCID: PMC7953885.